Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years

Documenti analoghi

• Synthesis of 2‐Aryl(alkyl)benzimidazole Hydroxamic Acids as HDAC Inhibitors with Anti‐Angiogenesis Properties
  di: Yi‐Ting Liu, et al.
  Pubblicazione: (2026)
• Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ 1 R Agonists/HDAC Inhibitor Dual‐Acting Compounds
  di: Antonino N. Fallica, et al.
  Pubblicazione: (2026)
• Selenocyanate‐Containing Molecules as Trypanosoma cruzi Inhibitors: Impact of Regioisomerism, Conformational Restriction, and Second‐Ring Substitution
  di: Hugo S. Steingrüber, et al.
  Pubblicazione: (2025)
• Evaluating Bis‐Phenacyl Bromide‐Based Bis‐Heterocyclic Templates as Anticancer Prototypes and Potential PARP1 Inhibitors
  di: Refaie M. Kassab, et al.
  Pubblicazione: (2025)
• Aminocholestane and Aminoandrostane Inhibitors of the SH2 Domain‐Containing Inositol 5’‐Phosphatase (SHIP)
  di: Angela M. Pacherille, et al.
  Pubblicazione: (2025)